Roanna Ruiz

Stock Analyst at Leerink Partners

(0.67)
# 2564
Out of 5,441 analysts
77
Total ratings
Success rate
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
AKBA Akebia Therapeutics
Initiates Coverage On: Outperform
7
3.35 108.96% 1 Apr 28, 2025
XERS Xeris Biopharma Hold...
Maintains: Outperform
5 6
7.21 -16.78% 5 Mar 7, 2025
CRMD Cormedix
Initiates Coverage On: Outperform
18
10.06 78.93% 1 Mar 7, 2025
LXRX Lexicon Pharmaceutic...
Downgrades: Market Perform
1
1.03 -2.91% 1 Mar 4, 2025
VIR Vir Biotechnology
Maintains: Outperform
18 20
4.28 367.29% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
26 27
16.38 64.84% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
3.87 235.92% 3 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
14
5.4 159.26% 1 Apr 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
330
300.44 9.84% 1 Feb 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
58
33.2 74.7% 1 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
25
71.95 -65.25% 1 Apr 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
9 2
2.18 -8.26% 4 Apr 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
49
6.48 656.17% 10 Feb 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
4.66 178.97% 7 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
8 6
3.5 71.43% 6 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
19
24.4 -22.13% 1 Dec 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
110 120
56.07 114.02% 3 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
75 50
7.45 571.14% 7 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
23 27
26.98 0.07% 7 Oct 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
60 40
14.88 168.82% 6 Oct 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
720 80
n/a n/a 3 Jul 14, 2022